Solvaprine

Solvaprine is white to off-white tablet, round, biconvex and plain on both sides.
Each tablet contains: Isoxsuprine Hydrochloride, USP 10 mg.

Pharmacology: Pharmacodynamics: Isoxsuprine hydrochloride is a beta2-adrenoceptor agonist that causes vasodilation by direct relaxation of vascular smooth muscle. Its beta2-adrenergic effects, however, are not essential to its vasodilating effect. Isoxsuprine decreases peripheral vascular resistance; blood pressure may be decreased by parental administration or large oral doses of isoxsuprine. Isoxsuprine may also have positive inotropic and chronotropic effects on the heart and may increase cardiac output.
Isoxsuprine also relaxes uterine smooth muscle and is valuable in arresting contractions in treated abortion and premature labor.
Mechanism of Action: Isoxsuprine is a vasodilator which also stimulate beta-adrenergic receptors. It causes direct relaxation of vascular and uterine smooth muscles and its vasodilation action is greater on the arteries supplying skeletal muscles than on those supplying skin. Isoxsuprine also produces positive inotropic and chronotropic effect.
Pharmacokinetics: Isoxsuprine hydrochloride is well absorbed in the gastrointestinal tract. The peak plasma concentration occurs about 1 hour after oral administration. The plasma half-life has been reported to be 1.5 hours. Isoxsuprine is excreted primary in the urine mainly as conjugates.

Isoxsuprine hydrochloride is primarily used to arrest premature labor. It has also been given in the treatment and management of cerebral and peripheral vascular disorders.

Initial dose of 10 mg to 20 mg three to four times daily or as prescribed by the physician.

Overdosage with isoxsuprine has not been reported. When this occurs, however, cardiovascular symptoms are expected. Overdosage with the oral format should be managed by gastric lavage. A nonselective fl-blocker may be administered intramuscularly if necessary.

Following recent arterial hemorrhage.
In patients with known heart disease.
In patients with severe anemia.

Isoxsuprine is contraindicated after recent arterial hemorrhage. It should not be given immediately post-partum, nor should it be used for premature labor if there is infection. In women being treated for premature labor, the risk of pulmonary edema means that extreme caution is required and the precautions and risk factors discussed under Salbutamol sulfate.

Ileus and respiratory distress syndrome has been found to be more common in the offspring of pregnant women who receive isoxsuprine. Incidence of respiratory distress syndrome increases as the isoxsuprine concentration on cord blood exceeds 10 mg/mL. The incidence of hypocalcemia and hypotension rises progressively with increasing isoxsuprine concentrations in the cord blood. Use isoxsuprine in pregnant women only when potential benefit outweighs the potential risk to mother and infants. There are reports of problems with isoxsuprine in breastfeeding babies.

Isoxsuprine may cause transient flushing, hypotension, tachycardia, rashes and gastrointestinal disturbances. Maternal pulmonary edema and fetal tachycardia have been reported following the intravenous administration of Isoxsuprine in premature labor.

Isoxsuprine may cause severe hypotension when administered with other vasodilators and anti-hypertensive drugs.

Store at temperatures not exceeding 30°C.

Drugs Acting on the Uterus / Peripheral Vasodilators & Cerebral Activators

C04AA01 - isoxsuprine ; Belongs to the class of 2-amino-1-phenylethanol derivative agents. Used as peripheral vasodilators.

Rx